Skip to main content
SpringerLink
Log in

Pathophysiology of Psoriasis/Novel Pathways

  • Chapter
  • First Online:
Advances in Psoriasis

  • 748 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 129.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Gottlieb A. Psoriasis. Dis Manag Clin Outcome. 1998;1:195–202.

    Article  Google Scholar 

  2. Gaspari AA. Innate and adaptive immunity and the pathophysiology of psoriasis. J Am Acad Dermatol. 2006;54(3 suppl 2):S67–80.

    Article  PubMed  Google Scholar 

  3. Di Cesare A, Di Meglio P, Nestle F. The IL-23/Th17 axis in the immunopathogenesis of psoriasis. J Invest Dermatol. 2009;129:1339–50.

    Article  PubMed  CAS  Google Scholar 

  4. Barker J. The pathophysiology of psoriasis. Lancet. 1991;338:227–30.

    Article  CAS  PubMed  Google Scholar 

  5. Nickoloff BJ, Nestle FO. Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities. J Clin Invest. 2004;113:1664–75.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Bos J, Meinardi M, van Joost T, et al. Use of cyclosporine in psoriasis. Lancet. 1989;23:1500–5.

    Article  Google Scholar 

  7. Khandke L, Krane J, Ashinoff R, et al. Cyclosporine in psoriasis treatment: inhibition of keratinocyte cell-cycle progression in G1 independent effects on transforming growth factor-alpha/epidermal growth factor receptor pathways. Arch Dermatol. 1991;127:1172–9.

    Article  CAS  PubMed  Google Scholar 

  8. Gottlieb S, Gilleaudeau P, Johnson R, et al. Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat Med. 1995;1:442–7.

    Article  CAS  PubMed  Google Scholar 

  9. Vallat V, Gilleaudeau P, Battat L, et al. PUVA bath therapy strongly suppresses immunological and epidermal activation in psoriasis: a possible cellular basis for remittive therapy. J Exp Med. 1994;180:283–96.

    Article  CAS  PubMed  Google Scholar 

  10. Gottlieb A, Grossman R, Khandke L, et al. Studies of the effect of cyclosporine in psoriasis in vivo: combined effects on activated T lymphocytes and epidermal regenerative maturation. J Invest Dermatol. 1992;98:302–9.

    Article  CAS  PubMed  Google Scholar 

  11. Gottlieb S, Hayes E, Gilleaudeau P, et al. Cellular actions of etretinate in psoriasis: enhanced epidermal differentiation and reduced cell-mediated inflammation are unexpected outcomes. J Cutan Pathol. 1996;23:404–18.

    Article  CAS  PubMed  Google Scholar 

  12. Nickoloff B, Bonish B, Huang B, et al. Characterization of a T cell line bearing natural killer receptors and capable of creating psoriasis in a SCID mouse model system. J Dermatol Sci. 2000;24:212–25.

    Article  CAS  PubMed  Google Scholar 

  13. Gillet M, Conrad C, Geiges M, et al. Psoriasis triggered by toll-like receptor 7 agonist imiquimod in the presence of dermal plasmacytoid dendritic cell precursors. Arch Dermatol. 2004;140:1490–5.

    Google Scholar 

  14. Funk J, Langeland T, Schrumpf E, et al. Psoriasis induced by interferon-alpha. Br J Dermatol. 1991;125:463–5.

    Article  CAS  PubMed  Google Scholar 

  15. Shiohara T, Kobayahsi M, Abe K, et al. Psoriasis occurring predominantly on warts: possible involvement of interferon alpha. Arch Dermatol. 1988;124:1816–21.

    Article  CAS  PubMed  Google Scholar 

  16. Fierlbeck G, Rassner G, Muller C. Psoriasis induced at the injection site of recombinant interferon gamma: results of immunohistologic investigations. Arch Dermatol. 1990;126:351–5.

    Article  CAS  PubMed  Google Scholar 

  17. Prinz J. The role of T cells in psoriasis. J Eur Acad Dermatol Venereol. 2003;17(suppl):1–5.

    Google Scholar 

  18. Bos J, de Rie M. The pathogenesis of psoriasis: immunological facts and speculations. Immunol Today. 1999;20:40–6.

    Article  CAS  PubMed  Google Scholar 

  19. Geginat J, Campagnaro S, Sallusto F, et al. TCR-independent proliferation and differentiation of human CD4+ T cell subsets induced by cytokines. Adv Exp Med Biol. 2002;512:107–12.

    Article  CAS  PubMed  Google Scholar 

  20. Kastelan M, Massari L, Brajac I. Apoptosis mediated by cytolytic molecules might be responsible for maintenance of psoriatic plaques. Med Hypotheses. 2006;67:336–7.

    Article  CAS  PubMed  Google Scholar 

  21. Austin L, Ozawa M, Kikuchi T, et al. The majority of epidermal T cells in psoriasis vulgaris lesions can produce type 1 cytokines, interferon-gamma, interleukin-2, and tumor necrosis factor-alpha, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: a type 1 differentiation bias is also measured in circulating blood T cells in psoriatic patients. J Invest Dermatol. 1999;113:752–9.

    Article  CAS  PubMed  Google Scholar 

  22. Abrams J, Kelley S, Hayes E, et al. Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plagues, including the activation of keratinocytes, dendritic cells and endothelial cells. J Exp Med. 2000;192:681–94.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Lebwohl M, Christophers E, Langley R, et al. An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol. 2003;139:719–27.

    Article  CAS  PubMed  Google Scholar 

  24. Krueger G, Ellis C. Alefacept therapy produces remission for patients with chronic plaque psoriasis. Br J Dermatol. 2003;148:784–8.

    Article  CAS  PubMed  Google Scholar 

  25. Gordon K, Leonardi C, Tyring S, et al. Efalizumab (anti-CD11a) is safe and effective in the treatment of psoriasis: pooled results of the 12-week first treatment period from 2 phase III trials. J Invest Dermatol. 2002;119:242.

    Google Scholar 

  26. Singh A, Wilson M, Hong S, et al. Natural killer T cell activation protects mice against experimental autoimmune encephalomyelitis. J Exp Med. 2001;194:1801–11.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Saubermann L, Beck P, De Jong Y, et al. Activation of natural killer T cells by alpha-glactosylceramide in the presence of CD1d provides protection against colitis in mice. Gastroenterology. 2000;119:119–28.

    Article  CAS  PubMed  Google Scholar 

  28. Campos R, Szczepanik M, Itakura A, et al. Cutaneous immunization rapidly activates liver invariant Valpha 14 NKT cells stimulating B-1 B cells to initiate T cell recruitment for elicitation of contact sensitivity. J Exp Med. 2003;198:1785–96.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Bonish B, Jullien D, Dutronc Y, et al. Overexpression of CD1d by keratinocytes in psoriasis and CD1d-dependent IFN-gamma production by NK-T cells. J Immunol. 2000;165:4076–85.

    Article  CAS  PubMed  Google Scholar 

  30. Deguchi M, Aiba S, Ohtani H, et al. Comparison of the distribution and numbers of antigen-presenting cells among T-lymphocyte-mediated dermatoses: CD1a+, factor XIIIa+, and CD68+ cells in eczematous dermatitis, psoriasis, lichen planus and graft-versus-host disease. Arch Dermatol Res. 2002;294:297–302.

    Article  CAS  PubMed  Google Scholar 

  31. Bos J, de Rie M, Teunissen M, et al. Psoriasis: dysregulation of innate immunity. Br J Dermatol. 2005;152:1098–107.

    Article  CAS  PubMed  Google Scholar 

  32. Trefzer U, Hofmann M, Sterry W, et al. Cytokine and anticytokine therapy in dermatology. Expert Opin Biol Ther. 2003;3:733–43.

    Article  CAS  PubMed  Google Scholar 

  33. Nickoloff B. The cytokine network in psoriasis. Arch Dermatol. 1991;127:871–84.

    Article  CAS  PubMed  Google Scholar 

  34. Victor F, Gottlieb A. TNF-alpha and apoptosis: implications for the pathogenesis and treatment of psoriasis. J Drugs Dermatol. 2002;3:264–75.

    Google Scholar 

  35. Oh C, Das K, Gottlieb A. Treatment with anti-tumour necrosis factor alpha (TNF-alpha) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesions. J Am Acad Dermatol. 2000;42:829–30.

    Article  CAS  PubMed  Google Scholar 

  36. Reich K, Nestle FO, Papp K, EXPRESS study investigators, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet. 2005;366:1367–74.

    Article  CAS  PubMed  Google Scholar 

  37. Leonardi C, Powers J, Matheson R, et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med. 2003;349:2014–22.

    Article  CAS  PubMed  Google Scholar 

  38. Saini R, Tutrone W, Weinberg J. Advances in therapy for psoriasis: an overview of infliximab, etanercept, efalizumab, alefacept, adalimumab, tazarotene, and pimecrolimus. Curr Pharm Des. 2005;11:273–80.

    Article  CAS  PubMed  Google Scholar 

  39. Cosmi L, De Palma R, Santarlasci V, et al. Human interleukin 17-producing cells originate from a CD161+CD4+ T cell precursor. J Exp Med. 2008;205:1903–16.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. de Beaucoudrey L, Puel A, Filipe-Santos O, et al. Mutations in STAT3 and IL12RB1 impair the development of human IL-17-producing T cells. J Exp Med. 2008;205:1543–50.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  41. Manel N, Unutmaz D, Littman DR. The differentiation of human T(H)-17 cells requires transforming growth factor-beta and induction of the nuclear receptor RORgammat. Nat Immunol. 2008;9:641–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Yang L, Anderson DE, Baecher-Allan C, et al. IL-21 and TGF-beta are required for differentiation of human T(H)17 cells. Nature. 2008;454:350–2.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Lee E, Trepicchio WL, Oestreicher JL, et al. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med. 2004;199:125–30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Chan JR, Blumenschein W, Murphy E, et al. IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis. J Exp Med. 2006;203:2557–87.

    Article  CAS  Google Scholar 

  45. Capon F, Di Meglio P, Szaub J, et al. Sequence variants in the genes for the interleukin-23 receptor (IL23R) and its ligand (IL12B) confer protection against psoriasis. Hum Genet. 2007;122:201–6.

    Article  CAS  PubMed  Google Scholar 

  46. Cargill M, Schrodi SJ, Chang M, et al. A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am J Hum Genet. 2007;80:273–90.

    Article  CAS  PubMed  Google Scholar 

  47. Nair RP, Ruether A, Stuart PE, et al. Polymorphisms of the IL12B and IL23R genes are associated with psoriasis. J Invest Dermatol. 2008;128:1653–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Ma HL, Liang S, Li J, et al. IL-22 is required for Th17 cell-mediated pathology in a mouse model of psoriasis-like skin inflammation. J Clin Invest. 2008;118:597–607.

    CAS  PubMed  PubMed Central  Google Scholar 

  49. Wolk K, Witte E, Wallace E, et al. IL-22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis. Eur J Immunol. 2006;36:1309–23.

    Article  CAS  PubMed  Google Scholar 

  50. Boniface K, Guignouard E, Pedretti N, et al. A role for T cell-derived interleukin 22 in psoriatic skin inflammation. Clin Exp Immunol. 2007;150:407–15.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Weaver CT, Hatton RD, Mangan PR, et al. IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu Rev Immunol. 2007;25:821–52.

    Article  CAS  PubMed  Google Scholar 

  52. Teunissen MB, Koomen CW, de Waal MR, et al. Interleukin-17 and interferon-gamma synergize in the enhancement of proinflammatory cytokine production by human keratinocytes. J Invest Dermatol. 1998;111:645–9.

    Article  CAS  PubMed  Google Scholar 

  53. Lowes MA, Kikuchi T, Fuentes-Duculan J, et al. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J Invest Dermatol. 2008;128:1207–11.

    Article  CAS  PubMed  Google Scholar 

  54. Arican O, Aral M, Sasmaz S, et al. Serum levels of TNF-alpha, IFN-gamma, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity. Mediat Inflamm. 2005;2005:273–9.

    Article  CAS  Google Scholar 

  55. Zaba LC, Cardinale I, Gilleaudeau P, et al. Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J Exp Med. 2007;204:3183–94.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Haider AS, Cohen J, Fei J, et al. Insights into gene modulation by therapeutic TNF and IFNgamma antibodies: TNF regulates IFNgamma production by T cells and TNF-regulated genes linked to psoriasis transcriptome. J Invest Dermatol. 2008;128:655–66.

    Article  CAS  PubMed  Google Scholar 

  57. Haider AS, Lowes MA, Suarez-Farinas M, et al. Identification of cellular pathways of “type 1,” Th17 T cells, and TNF- and inducible nitric oxide synthase-producing dendritic cells in autoimmune inflammation through pharmacogenomic study of cyclosporine a in psoriasis. J Immunol. 2008;180:1913–20.

    Article  CAS  PubMed  Google Scholar 

  58. Croxtall JD. Ustekinumab: a review of its use in the management of moderate to severe plaque psoriasis. Drugs. 2011;71:1733–53.

    Article  CAS  PubMed  Google Scholar 

  59. Gordon KB, Langely RG, Gottlieb AB, et al. A phase III, randomized, controlled trial of the fully human IL-12/23 mAb briakinumab in moderate-to-severe psoriasis. J Invest Dermatol. 2012;132:304–14.

    Article  CAS  PubMed  Google Scholar 

  60. Rahman P, Elder JT. Genetic epidemiology of psoriasis and psoriatic arthritis. Ann Rheum Dis. 2005;64(suppl 2):ii37–9.

    PubMed  PubMed Central  Google Scholar 

  61. Elder JT. PSORS1: linking genetics and immunology. J Invest Dermatol. 2006;126:1205–6.

    Article  CAS  PubMed  Google Scholar 

  62. Krueger JG, Bowcock A. Psoriasis pathophysiology: current concepts of pathogenesis. Ann Rheum Dis. 2005;64(suppl 2):ii30–6.

    CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Dermatology, University of Colorado, Aurora, CO, USA

    Jeremy M. Hugh

  2. Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA

    Jeffrey M. Weinberg

Authors
  1. Jeremy M. Hugh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jeffrey M. Weinberg
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jeffrey M. Weinberg .

Editor information

Editors and Affiliations

  1. Department of Dermatology, Suite 11D, Icahn School of Medicine at Mount Sinai, New York, NY, USA

    Jeffrey M. Weinberg

  2. Icahn School of Medicine at Mount Sinai, New York, NY, USA

    Mark Lebwohl

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Hugh, J.M., Weinberg, J.M. (2021). Pathophysiology of Psoriasis/Novel Pathways. In: Weinberg, J.M., Lebwohl, M. (eds) Advances in Psoriasis. Springer, Cham. https://doi.org/10.1007/978-3-030-54859-9_2

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-54859-9_2

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-54858-2

  • Online ISBN: 978-3-030-54859-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation